Investigation of Clinically Significant Molecular Aberrations in Patients with Prostate Cancer: Implications for Personalized Treatment, Prognosis and Genetic Testing
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241411834 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Elena Fountzilas und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, St. Lukes's Hospital, 55236 Thessaloniki, Greece. Hauptthemen laut MEDLINE: Precision Medicine, Prostatic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer, Hellenic Society of Medical Oncology, HeCOG.
Abstract (Originalsprache)
The data on tumor molecular profiling of European patients with prostate cancer is limited. Our aim was to evaluate the prevalence and prognostic and predictive values of gene alterations in unselected patients with prostate cancer. The presence of gene alterations was assessed in patients with histologically confirmed prostate cancer using the ForeSENTIA® Prostate panel (Medicover Genetics), targeting 36 clinically relevant genes and microsatellite instability testing. The primary endpoint was the prevalence of gene alterations in homologous recombination repair (HRR) genes. Overall, 196 patients with prostate cancer were evaluated (median age 72.2 years, metastatic disease in 141 (71.9%) patients). Gene alterations were identified in 120 (61%) patients, while alteration in HRR genes were identified in 34 (17.3%) patients. The most commonly mutated HRR genes were ATM (17, 8.7%), BRCA2 (9, 4.6%) and BRCA1 (4, 2%). The presence of HRR gene alterations was not associated with advanced stage (p = 0.21), age at diagnosis (p = 0.28), Gleason score (p = 0.17) or overall survival (HR 0.72; 95% CI: 0.41–1.26; p = 0.251). We identified clinically relevant somatic gene alterations in European patients with prostate cancer. These molecular alterations have prognostic significance and therapeutic implications and/or may trigger genetic testing in selected patients. In the era of precision medicine, prospective research on the predictive role of these alterations for innovative treatments or their combinations is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, St. Lukes's Hospital, 55236 Thessaloniki, Greece.
- Medical Oncology, German Oncology Center, European University Cyprus, Limassol 3036, Cyprus.
- Department of Basic and Clinical Sciences, University of Nicosia Medical School, Nicosia 2417, Cyprus.
- Medicover Genetics, Nicosia 2409, Cyprus.
- Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
- Oncology Unit, 2nd Department of Surgery, Aretaieio Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece.
ORCID-Profile: Alexia Eliades, Kyriakos Tsangaras, George Koumbaris, Ioannis Vakalopoulos, Soultana Meditskou, Athanasios Kotsakis, George Fountzilas
Förderung
- Pfizer
- Hellenic Society of Medical Oncology
- HeCOG
- University of Nicosia Medica School
Zitieren
APA
Fountzilas, E., Kouspou, M., Eliades, A., Papadopoulou, K., Bournakis, E., Goussia, A., Tsiatas, M., Achilleos, A., Tsangaras, K., Billioud, G., Loizides, C., Lemesios, C., Kypri, E., Ioannides, M., Koumbaris, G., Levva, S., Vakalopoulos, I., Paliouras, A., Pervana, S., …, & Patsalis, P. C. (2023). Investigation of Clinically Significant Molecular Aberrations in Patients with Prostate Cancer: Implications for Personalized Treatment, Prognosis and Genetic Testing. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241411834
Vancouver
Fountzilas E, Kouspou M, Eliades A, Papadopoulou K, Bournakis E, Goussia A, et al. Investigation of Clinically Significant Molecular Aberrations in Patients with Prostate Cancer: Implications for Personalized Treatment, Prognosis and Genetic Testing. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241411834
BibTeX
@article{Fountzilas2023,
author = {Fountzilas, Elena and Kouspou, Maria and Eliades, Alexia and Papadopoulou, Kyriaki and Bournakis, Evangelos and Goussia, Anna and Tsiatas, Marinos and Achilleos, Achilleas and Tsangaras, Kyriakos and Billioud, Gaetan and Loizides, Charalambos and Lemesios, Christos and Kypri, Elena and Ioannides, Marios and Koumbaris, George and Levva, Sofia and Vakalopoulos, Ioannis and Paliouras, Athanasios and Pervana, Stavroula and Koinis, Filippos and Bumci, Redi and Christopoulou, Athina and Meditskou, Soultana and Psyrri, Amanda and Boukovinas, Ioannis and Visvikis, Anastasios and Karavasilis, Vasilios and Koukoulis, George K and Kotsakis, Athanasios and Giannakis, Dimitrios and Fountzilas, George and Patsalis, Philippos C},
title = {Investigation of Clinically Significant Molecular Aberrations in Patients with Prostate Cancer: Implications for Personalized Treatment, Prognosis and Genetic Testing},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241411834}
}
EUVIMED